MP Healthcare Venture Management
VC Fund
Boston, United States
MP Healthcare Venture Management is a VC fund in Boston focused on Biotechnology and Health Care. MPH is the venture capital arm of Mitsubishi Tanabe Pharma Corporation (MTPC). MPH invests in innovative companies developing novel therapeutics, platform technologies, and vaccines.
- Total investments:
- 48
- Last investment:
- Lead investor:
- 10%
Last updated:
For AI agents: llms.txt
Industries MP Healthcare Venture Management invests in
Stages MP Healthcare Venture Management invests in
Countries MP Healthcare Venture Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 26 (54%)
- Health Care 14 (29%)
- Therapeutics 11 (23%)
- Pharmaceutical 7 (15%)
- Medical 6 (13%)
Stage
- Seed 11 (23%)
- Series B 10 (21%)
- Series A 8 (17%)
- Series C 5 (10%)
- Funding Round 2 (4%)
Country
- United States 13 (27%)
- Switzerland 3 (6%)
- United Kingdom 3 (6%)
- Canada 2 (4%)
- Italy 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jeffrey Moore
President & Board Member
|
President & Board Member | Total investments: 6 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
TRIMTECH Therapeutics
|
TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $14M / Seed / Jun 23, 2026 | |
GlycoEra
|
GlycoEra is a CustomGlycan platform that unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics. | $130M / Series B / May 27, 2025 | |
|
TRIMTECH Therapeutics
|
TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $31M / Seed / Mar 05, 2025 | |
Libero Thera
|
LiberoThera provides drug discovery research and development services. It focuses on making drugs with GPCRs for membrane proteins. LiberoThera was founded in 2018 and is located in Tokyo. | $1.3M / Venture - Series Unknown / Aug 01, 2024 | |
Draupnir Bio
|
Draupnir Bio intends to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company is developing a platform for exploring the glycome to develop novel therapeutics, based on array technology, protein chemistry, and advanced carbohydrate chemistry. The company isable to synthesize, screen, and select highly potent and specific heparan sulfate glycomimetic drug candidates in cardiovascular, inflammatory, and infectious diseases. | $13.2M / Seed / Jul 17, 2024 | |
Outrun TX
|
Outrun TX develops a platform for the identification of therapeutics that selectively target the protein degradation pathway. | $10M / Seed / Apr 18, 2024 | |
PharmEnable
|
PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery of vital new medicines. | $7.5M / Seed / May 22, 2023 | |
|
PharmEnable
|
PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery of vital new medicines. | $7.5M / Seed / May 22, 2023 | |
QurAlis
|
QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $88M / Series B / Mar 09, 2023 | |
Korro Bio
|
Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in proteinstructure and function across multiple tissues.In 2018, | $116M / Series B / Jan 05, 2022 | |
| See all 48 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does MP Healthcare Venture Management invest in?
MP Healthcare Venture Management invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Series B stage. Most of the 48 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact MP Healthcare Venture Management?
Public channels for MP Healthcare Venture Management include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at MP Healthcare Venture Management?
The team at MP Healthcare Venture Management includes Jeffrey Moore (President & Board Member). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
